HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sooriakumaran, P Search for Related Content PubMed PubMed Citation Articles by Sooriakumaran, P

COX-2 inhibitors and the heart: are all coxibs the same?

Correspondence to:
Correspondence to:
Mr P Sooriakumaran
Postgraduate Medical School, University of Surrey, Manor Park, Daphne Jackson Road, Guildford, Surrey, UK; p.s{at}doctors.org.uk

The selective COX-2 inhibitors (coxibs) were originally developed to minimise the adverse effects of conventional non-steroidal anti-inflammatory drugs (NSAIDs) while maintaining the same analgesic and anti-inflammatory properties. Many large studies confirmed the improved gastric side effect profile of coxibs compared with non-selective NSAIDs; however, reports of increased cardiovascular morbidity and mortality followed, and the manufacturer Merck was forced to withdraw rofecoxib (Vioxx) from the market. Other coxibs have also either perished or had restrictions placed on their use. However, there seem to be significant differences between coxibs regarding their cardiovascular profiles, and the evidence for a class effect is dubious. In this paper, the current body of knowledge regarding the cardiovascular toxicities of coxibs is reviewed. The take home message for prescribing NSAIDs and those coxibs still on the market seems to be one of caution rather than contraindication, except in patients with significant cardiovascular risk factors.

Abbreviations: NSAID, non-steroidal anti-inflammatory drug; COX-2, cyclo-oxygenase-2

Keywords: coxibs; cardiovascular risk; celecoxib; cyclo-oxygenase-2 inhibitors

This article has been cited by other articles:

				J. Si, X. Fu, J. Behar, J. Wands, D. G. Beer, R. F. Souza, S. J. Spechler, D. Lambeth, and W. Cao NADPH Oxidase NOX5-S Mediates Acid-induced Cyclooxygenase-2 Expression via Activation of NF-{kappa}Bin Barrett's Esophageal Adenocarcinoma Cells J. Biol. Chem., June 1, 2007; 282(22): 16244 - 16255. [Abstract] [Full Text] [PDF]